Scientists in America have developed an automated three-dimensional cell-imaging platform aimed at detection of lung cancer in sputum.
The Lung Cell Evaluation Device (LuCED), jointly developed by experts from VisionGate, Inc. and the University of Washington, can detect pre-cancerous and cancerous cells in sputum.
Novel Method To Keep Track Of Lung Cancer Treatment
Australian researchers have evolved a novel way of keeping track of the progress of lung cancer treatment.
Australian researchers have evolved a novel way of keeping track of the progress of lung cancer treatment.
They have revealed that LuCED automatically produces 3D cell volumetric data, allowing for the measurement of 3D cellular features that correlate with abnormal conditions.
They say that the cell measurements are then translated into an analytical score that reflects the patient's cancer risk.
Surgery May Benefit Advanced Lung Cancer Patients
Surgery after standard chemotherapy and radiation can be an option for patients with a certain type of advanced lung cancer.
Surgery after standard chemotherapy and radiation can be an option for patients with a certain type of advanced lung cancer.
"Based on abnormal cell prevalence counts in sputum from patients with cancer, we estimate that the LuCED test demonstrates near-perfect specificity (no false positives) while maintaining sensitivity that exceeds 90 percent for patients with lung cancer cells in their sputum," says Michael Meyer, lead author and vice president for image engineering at VisionGate.
Advertisement
European Union Rules Out Erbitux for Lung Cancer
The European Union has rejected Erbitux drug for treatment of lung cancer, denting growth prospects for the company’s top-selling oncology treatment.
The European Union has rejected Erbitux drug for treatment of lung cancer, denting growth prospects for the company’s top-selling oncology treatment.
Meyer will present the findings of the study at the Moscone Center in California on Tuesday.
Advertisement
ARU
